ICLR
ICON Public Limited Company · Healthcare · Medical - Diagnostics & Research
Momentum inputs (comparable managers):
holder breadth -7.7% ·
share flow -3.0% ·
net new positions -8.3%
— formula
Broad distribution — falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q4 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 113 | +2 | 54.24M | $9.34B | +10 | −7 |
| Q1 2026 | 112 | -7 | 49.87M | $5.61B | +7 | −15 |
| Q4 2025 | 119 | -2 | 53.17M | $9.70B | +2 | −3 |
| Q3 2025 | 18 | -1 | 14.11M | $2.47B | +2 | −4 |
| Q2 2025 | 17 | +3 | 17.03M | $2.48B | +3 | — |
| Q1 2025 | 11 | -1 | 10.01M | $1.75B | +1 | −2 |
| Q4 2024 | 12 | -1 | 9.48M | $1.99B | +2 | −3 |
| Q3 2024 | 12 | -1 | 9.43M | $2.71B | +1 | −2 |
| Q2 2024 | 13 | — | 9.47M | $2.97B | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | T. Rowe Price ✦ | 2.93M | -12.4% | $615.20M | 0.1% | ▼ Trim | 3 | SEC ↗ |
| 2 | T. Rowe Price ✦ | 2.93M | -12.4% | $615.20M | 0.1% | ▼ Trim | 3 | SEC ↗ |
| 3 | Wellington Management ✦ | 2.11M | -31.4% | $443.17M | 0.1% | ▼ Trim | 3 | SEC ↗ |
| 4 | Wellington Management ✦ | 2.11M | -31.4% | $443.17M | 0.1% | ▼ Trim | 3 | SEC ↗ |
| 5 | Wellington Management ✦ | 2.11M | -31.4% | $443.17M | 0.1% | ▼ Trim | 3 | SEC ↗ |
| 6 | Wellington Management ✦ | 2.11M | -31.4% | $443.17M | 0.1% | ▼ Trim | 3 | SEC ↗ |
| 7 | Wellington Management ✦ | 2.11M | -31.4% | $443.17M | 0.1% | ▼ Trim | 3 | SEC ↗ |
| 8 | Wellington Management ✦ | 2.11M | -31.4% | $443.17M | 0.1% | ▼ Trim | 3 | SEC ↗ |
| 9 | Wellington Management ✦ | 2.11M | -31.4% | $443.17M | 0.1% | ▼ Trim | 3 | SEC ↗ |
| 10 | Wellington Management ✦ | 2.11M | -31.4% | $443.17M | 0.1% | ▼ Trim | 3 | SEC ↗ |
| 11 | D. E. Shaw & Co. ✦ | 1.12M | +574.6% | $234.08M | 0.3% | ▲ Add | 3 | SEC ↗ |
| 12 | D. E. Shaw & Co. ✦ | 1.12M | +574.6% | $234.08M | 0.3% | ▲ Add | 3 | SEC ↗ |
| 13 | Norges Bank ✦ (passive) | 1.01M | +0.2% | $211.05M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 14 | Point72 Asset Management ✦ | 856.70K | +649.7% | $179.66M | 0.5% | ▲ Add | 3 | SEC ↗ |
| 15 | Citadel Advisors ✦ | 571.61K | -1.5% | $119.87M | 0.1% | ▼ Trim | 3 | SEC ↗ |
| 16 | Citadel Advisors ✦ | 571.61K | -1.5% | $119.87M | 0.1% | ▼ Trim | 3 | SEC ↗ |
| 17 | State Street Global Advisors ✦ (passive) | 340.78K | — | $71.46M | 0.0% | n/c | 1 | SEC ↗ |
| 18 | Millennium Management ✦ | 225.63K | -70.9% | $47.32M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 19 | Renaissance Technologies ✦ | 125.80K | -40.7% | $26.38M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 20 | Marshall Wace ✦ | 88.74K | New | $18.61M | 0.0% | New | 1 | SEC ↗ |
| 21 | Marshall Wace ✦ | 88.74K | New | $18.61M | 0.0% | New | 1 | SEC ↗ |
| 22 | Geode Capital Management ✦ (passive) | 84.34K | +1.1% | $17.69M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 23 | Adage Capital Partners ✦ | 19.68K | New | $4.13M | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Marshall Wace | $18.61M | 0.0% |
| Marshall Wace | $18.61M | 0.0% |
| Adage Capital Partners | $4.13M | 0.0% |
Exited
| Arrowstreet Capital | $16.17M | was 0.0% |
| Fisher Asset Management | $1.58M | was 0.0% |
| Capital World Investors | $380,398 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 414 holders, 78.10M shares, $8.66B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 105 sh · $17,196
Director · 67 sh · $11,089
Director · 280 sh · $45,562
Director · 305 sh · $49,950
Director · 1.88K sh · $309,204
Director · 212 sh · $35,088
Director · 95 sh · $15,458
Director · 642 sh · $105,590
Director · 73 sh · $12,082
Director · 88 sh · $14,319
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology